TNFRSF11A and osteoporosis: The drug denosumab prevents bone resorption by inhibiting the nuclear factor kappa-B (NF-κB) pathway by blocking the binding of RANKL to RANK, which is expressed on the surface of osteoclast precursor cells and mature osteoclasts, and is considered important for the treatment of osteoporosis [105].